Trial Profile

A Phase 2, Randomized, Multicenter, Open-label Study of DCC-2618 (Ripretinib, ZL-2307 ) vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Jan 2024 According to a Deciphera Pharmaceuticals media release, results of a ctDNA analysis from this trial will be published in the Nature Medicine in January 2024.
14 Nov 2023 Primary endpoint (PFS assessed by independent central review) has been met, as per results published in the European Journal of Cancer.
14 Nov 2023 Results assessing the efficacy and safety (data cut-off 20 July 2022) of ripretinib versus sunitinib as second-line treatment in Chinese gastrointestinal stromal tumor patients, published in the European Journal of Cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com